Fig. 3
Decrease in ADMA concentration in relation to the number of delivered BM-MNCs at 3 months after cell delivery. ADMA asymmetric dimethylarginine, BM-MNC bone marrow-derived mononuclear cell
Fig. 3 | Stem Cell Research & Therapy